SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Torrey Pines Investment announced today the launch and initial funding of its i2020 Accelerator initiative. With Torrey Pines funding of up to US$30 million, i2020 implements agile development principles to accelerate small molecules with clearly established development paradigms and paths towards clear differentiation and competitive edge as advanced leads and clinical candidates.
The i2020 plan calls for multiple projects, sourced from international scouting and external partners, with selections based on first-in-class or best-in-class status, strong clinical hypothesis, well-defined Target Product Profile and development milestones, preference is given to validated biomarkers, established druggability and similar criteria.
i2020 projects will have an immunocentric focus, but will be broadly drawn from the areas of inflammation, oncology, CNS, and infectious diseases. Ten to fifteen programs are planned in the first generation of i2020.
Partners are sought to source qualified programs; participate through flexible business models including in-kind and financial resources; and options on pre-commercial projects, non-equity participation with predefined takeout, and out-licensing upon achievement of a Target Product Profile.
About Torrey Pines Investment
Torrey Pines Investment (San Diego, CA) is a specialty life-science investment firm. Torrey Pines invests in development stage molecules, diagnostics, and therapeutics in areas of high unmet medical need. [www.torreypinesinv.com]